Drug Profile
Research programme: antibodies - Adimab/Boehringer Ingelheim
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Adimab
- Developer Adimab; Boehringer Ingelheim
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Unspecified in USA (Parenteral)
- 10 Jan 2018 Adimab and Boehringer Ingelheim enter into a collaboration agreement to develop monoclonal and bispecific antibodies
- 10 Jan 2018 Early research in Undefined indication in USA (Parenteral)